Anti-CD33 (gemtuzumab biosimilar) mAb

Figure 1. HEK293 cell line transfected with irrelevant protein  (B) and human CD33  (A) were surface stained with anti-CD33 neutralizing antibody 1μg/ml (gemtuzumab) followed by Alexa 488-conjugated anti-human IgG secondary antibody.

Figure 2. Flow cytometry analysis of antigen binding of anti-human CD33 mAb(BME100015).
(A) A clear peak shift of BME100015 was seen compared to the control when incubated with CD33-expressing 8226 cells, indicating strong binding of BME100015 to CD33. Antibodies were incubated at 2 μg/mL.

Figure 3. Flow cytometry analysis of antigen binding of anti-human CD33 mAb(BME100015).
(A) BME100015 does not bind to 293T cells that do not express CD33.
(B) A clear peak shift of BME100015 was seen compared to the control when incubated with CD33 -expressing THP-1 cells, indicating strong binding of BME100015 to CD33 . Antibodies were incubated at 5 μg/mL.